FORMULATION AND EVALUATION OF TOPICAL FORMULATION FOR CUTANEOUS TUBERCULOSIS

  • Monica Rao Department of Pharmaceutics, AISSMS College of Pharmacy, Near RTO, Kennedy Road, Pune -411001, India
  • Manali Kadam Department of Pharmaceutics, AISSMS College of Pharmacy, near RTO, Kennedy Road, Pune -411001, India
  • Shivani Rao Department of Pharmaceutics, AISSMS College of Pharmacy, near RTO, Kennedy Road, Pune -411001, India

Abstract

Cutaneous Tuberculosis is also known as dermal tuberculosis or tuberculosis cutis (extrapulmonary tuberculosis) which can occur in any age group and patients who may or may not be suffering from pulmonary tuberculosis. The current treatment given for the disease is oral therapy of anti-tubercular drugs which has many side effects such as hepatotoxicity, headache, anxiety, euphoria, insomnia, eosinophilia, hepatitis. Hence to avoid these side effects and to increase efficiency of current therapy a topical proniosomal gel of isoniazid was formulated. Coacervation phase separation method was used and proniosomal gel was formulated by using Span 20, soya lecithin, and cholesterol. Optimum concentration of 3 factors Span 20, soya lecithin, and cholesterol were determined using Box Behnken design with at 2 levels and vesicle size and entrapment efficiency as responses. The optimized proniosomal gel was characterized by vesicle size, entrapment efficiency, transmission electron microscopy (TEM), in vitro drug release, skin retention studies, skin irritation studies and stability studies. The optimised batch showed vesicle size of 2.27±1.82 µ, and entrapment efficiency of 98.15±0.25 %. The optimised formulation was stable under refrigeration condition (5°C) in amber coloured bottle, was non-irritating and showed 98.10±1.28 % release and 85±1.53 % permeation after 6 h and 436±12 µg drug was retained in the skin after 3 hrs.

Keywords: Cutaneous tuberculosis, isoniazid, proniosomal gel, stability

 

Downloads

Download data is not yet available.

Author Biographies

Monica Rao, Department of Pharmaceutics, AISSMS College of Pharmacy, Near RTO, Kennedy Road, Pune -411001, India

Department of Pharmaceutics, AISSMS College of Pharmacy, near RTO, Kennedy Road, Pune -411001, India

Manali Kadam, Department of Pharmaceutics, AISSMS College of Pharmacy, near RTO, Kennedy Road, Pune -411001, India

Department of Pharmaceutics, AISSMS College of Pharmacy, near RTO, Kennedy Road, Pune -411001, India

Shivani Rao, Department of Pharmaceutics, AISSMS College of Pharmacy, near RTO, Kennedy Road, Pune -411001, India

Department of Pharmaceutics, AISSMS College of Pharmacy, near RTO, Kennedy Road, Pune -411001, India

References

1. Frankel A, Penrose C, Emer J, Cutaneous Tuberculosis A Practical Case Report and Review for The Dermatologist, Am J Clin AesthDerm, 2009; 2:19-27.
2. Caona T, Camposb CEM, Simõesa CMV, Silvaa MAS, Novel perspectives in the tuberculosis treatment: Administration of isoniazid through the skin, Int J Pharm, 2015; 494 (1):463–470.
3. Zy LV, du Plessis J, Viljoen J, Cutaneous tuberculosis overview and current treatment regimens. Tuberculosis, 2015; 95,:629-638.
4. Loukia, A., Joseph, S., Brian, B., Nicole, A., & Zacharie, K. Multidrug resistant tuberculosis in children in the democratic republic of Congo: First experience with a short treatment course in a university hospital. Journal of Drug Delivery and Therapeutics, 2018; 8(2):123-128. doi:10.22270/jddt.v8i2.1682
5. Chen S, MQin, Han Y, Zhao L, Fu Y, Shang Y et al, Assessment of the efficacy of drug transdermal delivery by electro-phonophoresis in treating tuberculous lymphadenitis, Drug Deliv, 2016,; 23(5):1588–1593.
6. Chen S, Han Y, Yu D, Huo F, Wang F, Li Y et al, Transdermal delivery of isoniazid and rifampin in guinea pigs by electro-phonophoresis, Drug Deliv, 2017; 24(1):467–470.
7. Bhutani H, Singh S, Vir S, Bhutani KK, Kumar R, Chakraborti AK et al, LC and LC-MS study of stress decomposition behaviour of isoniazid and establishment of validated stability-indicating assay method, J Pharm Biomed Anal, 2007; 43:1213–1220.
8. Bolmal U.B, Pandey C.K, Phatarpekar V, Dhople N.G, and Kotha Rajkumar, Preparation and Evaluation of Isoniazid and Rifampicin Dispersible Tablets Prepared by Direct Compression and Sublimation Method. Int J Pharm Sci Nanotech,2013; 6(4):2225-2236.
9. Chang R, Raw A, Lionberger R and Yu L, Generic Development of Topical Dermatologic Products: formulation Development, Process Development, and Testing of Topical Dermatologic Products, AAPS J,2013; 15:41-52.
10. Desai D, Shah M, A Review: Validated Analytical Methods Developed on Antitubercular Drug, Rifampicin. J of Pharm Sci Biosci Res, 2015; 5:254-265.
11. Mishra A, Kapoor A, Bhargava S, Proniosomal Gel as a Carrier for Improved Transdermal Drug-Delivery, Asian J Pharm Life Sci,2011; 1(4):370-379.
12. Mehta M, Garg M. Proniosomal Gel: A Promising Drug Carrier for Boswellic Acids, J Med Sci. 2015; 15(3):130-134.
13. Indian Pharmacopoeia,The Indian Pharmacopoeia Commission Ghaziabad. 2007; 2:629-630.
14. ICH Harmonised Tripartite Guideline, Stability Testing of New Drug Substances and Products Q1A(R2). Step 4 Version Dated 6 Feb 2003.
15. Krilla MA, Das D, John G. Augustine, Semisolid Formulation, Development: The CRO Approach. SP formulations, Wareham 2009; 1-12.
16. Doaa A. Helal, Dalia Abd El-Rhman, Sally A. Abdel-Halim, Mohamed A. El-Nabarawi, Formulation and Evaluation of Fluconazole Topical Gel, Int J Pharmacy Pharm Sci. 2012; 4:176-183.
17. Perrett, S., M. Golding and W.P. Williams, A simple method for the preparation of liposomes for pharmaceutical applications: Characterization of the liposomes, J. Pharm. Pharmacol, 1991; 43:54-161.
18. Singh G, Dwivedi H, Saraf SK, Saraf SA, Niosomal Delivery of Isoniazid - Development and Characterization, Trop J Pharm Res, 2011; 10(2):203-210.
19. Patel KK, Kumar P, Thakkar HP, Formulation of Niosomal Gel for Enhanced Transdermal Lopinavir Delivery and Its Comparative Evaluation with Ethosomal Gel, AAPS Pharm SciTech,2012; 13(4):1502-1510.
20. Asthana GS, Asthana A, Singh D, Sharma PK, Etodolac Containing Topical Niosomal Gel: Formulation Development and Evaluation, Drug Deliv, 2016; 1-9.
21. Sandeep G, Vasavi Reddy D, Srinivas Reddy Devireddy, Formulation and Evaluation of Fluconazole Pro-Niosomal Gel for Topical Administration, J App Pharm Sci,2014; 4(7):98-104.
22. Mishra S, Vasistha P, Sachdeva M, Sara U V S, Formulation, Optimization and Characterization of Proniosomal Gel For Transdermal Delivery Of Naproxen, Int J Uni Pharm Life Sci. 2013; 3(3):145-161.
23. Budhiraja A, Dhingra G, Development and characterization of a novel antiacne niosomal gel of rosmarinic acid, Drug Deliv, 2015, 22(6):723–730.
24. Rajabalaya R, Leen G, Chellian J, shrikumar chakravarthi, sheba. R. David, Tolterodine tartarate Proniosomal gel transdermal delivery for overactive bladder, Pharmaceutics, 2016; 8(27):2-15.
25. Kamboj S, Saini V, Bala S, Sharma G, Formulation and Characterization of Drug Loaded Niosomal Gel for Anti-Inflammatory Activity, Int J Pharmacol and Pharm Sci. 2013; 7(12):877-881.
26. Qumbar M, Ameeduzzafar, Imam SS, Javed Ali, J Ahmad, Ali A, Formulation and optimization of lacidipine loaded niosomal gel for transdermal delivery: In-vitro characterization and in-vivo activity, Biomed &Pharmacother,2017; 93:255–266.
27. Patil HN, Hardikar SR, Bhosale AV, Formulation Development & Evaluation of Proniosomal Gel of Carvedilol, Int J Pharm Pharma Sci.2012; 4(1):191-197.
28. Vasistha P, Ram A, Proniosomes, as a Drug Carrier for Transdermal Delivery of Hydrochlorothiazide and Lisinopril Combination. Int J of Pharm and Pharma Sci. 2013; 5:142-149.
29. Prasad V, Chaurasia S, Performance evaluation of non-ionic surfactant based tazarotene encapsulated proniosomal gel for the treatment of psoriasis, Materials Sci and Eng, 2017; C(79):168–176.
30. Sambhakara S, Paliwala S, Sharmaa S, Singh B, Formulation of risperidone loaded proniosomes for effective transdermal delivery: An in-vitro and in-vivo study, Bulletin Fac Pharma. 2017; 55(2):1-9.
31. Rahman SA, Abdelmalak NS, Badawi A, Elbayoumy T, Sabry N, El Ramly A, Formulation of tretinoin-loaded topical proniosomes for treatment of acne: in-vitro characterization, skin irritation test and comparative clinical study, Drug Deliv, 2015; 22(6):731–739.
32. Ruela ALM, Perissinato AG, Monica Esselin de Sousa Lino, Paula Silva Mudrik, Gislaine Ribeiro Pereira, Evaluation of skin absorption of drugs from topical and transdermal formulations, Brazilian J Pharm Sci, 2016; 52:527-544.
33. Brewer GA, Isoniazid, in: K. Florey (Ed 1), Analytical Profiles of Drug Substances, London:Academic; 1976; 8:184–258.
34. Razak SA, Yaacob SFFS, Abdullah JM, Adnan R. Isoniazid and β-cyclodextrin complexes, A stability study in aqueous solution, J ChemPharm Res, 2015; 7(7):346-355.
35. https://pubchem.ncbi.nlm.nih.gov/compound/isoniazid#section=LogS (2018) Accessed 12th March 2018.
36. Sandra Stets, Bianca do Amaral, Jéssica Tamara Schneider, Ivan Ricardo de Barrosa, Marcus Vinícius de Liz, Ronny Rocha Ribeiro et al, Antituberculosis drugs degradation by UV-based advanced oxidation processes, J of Photochem and Photobio A: Chem, 2018; 353:26–33.
37. http://www.ajhp.org/content/75/10/622(2018) Accessed on 6th July 2018.
38. Shukla, N.D. and M. Tiwari, Proniosomal drug delivery system-clinical applications, Int. J. Res. Pharm. Biomed. Sci. 2011; 2:880-887.
39. Mokhtar, M., O.A. Sammour, M.A. Hammad and N.A. Megrab, Effect of formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes, Int J Pharm,2008,361,104-111.
40. Benipal G, Design, Development and Evaluation of Proniosomal Gel of an Antifungal Drug – Ketoconazole, Int J Pharm Sci RevRes, 2015; 31(2):265-272.
41. Varshosaz J, Pardakhty A, Hajhashemi V, Najafabadi AR, Development and Physical Characterization of Sorbitan Monoester Niosomes for Insulin Oral Delivery,Drug Deliv, 2003; 10:251–262.
42. Shatalebi MA, Mostafavi SA, Moghaddas A. Niosome as a drug carrier for topical delivery of N-acetyl glucosamine, Res PharmSci, 2010; 5:107–17.
43. Pankaj S, Rini T, Dandagi PM, Formulation and Evaluation of Proniosome Based Drug Delivery System of The Antifungal Drug Clorimazole, Int J of Pharm SciNanosci,2013; 6:1945-1951.
44. Lather V, Sharma D, Pandita D, Proniosomal Gel-Mediated Transdermal Delivery of Bromocriptine: In Vitro And Ex Vivo Evaluation, J of Exp Nanosci,2016; 11(13):1044-1057.
45. El-Laithy HM, Shoukry O, Mahran LG, Novel sugar esters proniosomes for transdermal delivery of vinpocetine: Preclinical and clinical studies, Europ J PharmBiopharm, 2011; 77(1):43-55.
46. El Maghraby GM, Ahmed AA, Osman MA, Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery, Saudi Pharm J. 2015; 23(1):67–74.
47. Solanki AB, Parikh JR, Parikh RH, Formulation and Optimization of Piroxicam Proniosomes by 3-Factor, 3-Level Box-Behnken Design, AAPS Pharm SciTech, 2007; 8(4):1-7.
48. Shehata TM, Abdallah MH, Ibrahim MM, Proniosomal Oral Tablets for Controlled Delivery and Enhanced Pharmacokinetic Properties of Acemetacin, AAPS PharmSciTech, 2015,16; 375-383.
49. Alli MS, Srilakshmi.Ch, Ganesan G. Proniosome Gel: An Effective Novel Therapeutic Topical Delivery System, Int J of PharmTech Res, 2013; 5:1754- 1764.
50. Ibrahim MMA, Sammour OA, Hammad MA, Megrab NA, In Vitro Evaluation of Proniosomes as a Drug Carrier for Flurbiprofen, AAPS PharmSciTech, 2008; 9:782-790.
51. Udasi TA, Wankhade VP, Ingle LM, Atram S, Tapar KK, Proniosome: A Novel Approach to Vesicular Drug Delivery System, Int J Pharm and Pharm Sci Res. 2013; 3(1):1-6.
52. Radha G.V., Veerendranath Chowdary CH., Formulation and Evaluation of Ornidazole Proniosomal Gel, Indo Am J of Pharm Res,2014; 4:2657-2664.
53. Mehta S.K., Jindal N, Formulation of Tyloxapol niosomes for encapsulation, stabilization and dissolution of anti-tubercular drugs, Colloids and Surfaces B: Biointerfaces,2013; 101:434– 441.
Statistics
69 Views | 181 Downloads
How to Cite
Rao, M., Kadam, M., & Rao, S. (2018). FORMULATION AND EVALUATION OF TOPICAL FORMULATION FOR CUTANEOUS TUBERCULOSIS. Journal of Drug Delivery and Therapeutics, 8(4), 102-116. https://doi.org/10.22270/jddt.v8i4.1723